Jennifer Lachey - Apr 4, 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Apr 4, 2022
Transactions value $
-$474,615
Form type
4
Date filed
4/6/2022, 04:49 PM
Previous filing
Mar 15, 2022
Next filing
Apr 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $2.39K +7.95K +9.28% $0.30* 93.7K Apr 4, 2022 Direct
transaction KROS Common Stock Sale -$477K -7.95K -8.49% $60.00 85.7K Apr 4, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS of Shares Employee Stock Option (right to buy) Options Exercise $0 -7.95K -9.39% $0.00 76.7K Apr 4, 2022 Common Stock 7.95K $0.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 Immediately exercisable.